Opaleye Management Inc. filed a Form 4 on October 26, 2026, disclosing two open-market purchases of Grace Therapeutics, Inc. common stock made on October 22 and October 26, 2026, bringing its indirect beneficial ownership to 3,036,411 shares.

Key Highlights

  • First purchase: 21,390 shares of Grace Therapeutics common stock acquired on October 22, 2026, at a weighted average price of $1.9258 per share, with individual transaction prices ranging from $1.91 to $1.93.
  • Second purchase: 66,411 shares acquired on October 26, 2026, at a weighted average price of $1.7679 per share, with individual transaction prices ranging from $1.705 to $1.79.
  • Combined shares acquired: 87,801 shares purchased across the two reported transactions.
  • Resulting ownership: Opaleye Management Inc. reported indirect beneficial ownership of 3,036,411 shares following the October 26 transaction, held through Opaleye, L.P.
  • Ownership threshold: Opaleye Management Inc. is identified as a 10% owner of Grace Therapeutics, Inc.
  • Disclaimer noted: Opaleye Management Inc. "disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein," according to the filing.

Opaleye Management's Two-Day Accumulation of Grace Therapeutics Common Stock

According to the filing, Opaleye Management Inc., headquartered in Boston, Massachusetts, reported two separate purchases of Grace Therapeutics, Inc. (NASDAQ:GRCE) common stock, par value $0.0001 per share. The first transaction, dated October 22, 2026, involved the acquisition of 21,390 shares at a weighted average price of $1.9258. The filing notes those shares were purchased across multiple transactions at prices ranging from $1.91 to $1.93 per share.

The second transaction, dated October 26, 2026, involved the acquisition of 66,411 shares at a weighted average price of $1.7679 per share. The filing discloses that those shares were also purchased in multiple transactions, with prices ranging from $1.705 to $1.79. Both purchases are coded "P," indicating open-market purchases. The filing states that Opaleye Management Inc. undertakes to provide full information on shares purchased at each separate price within the reported ranges, upon request by the SEC staff, the issuer, or a security holder.

All shares are held indirectly through Opaleye, L.P., the fund for which Opaleye Management Inc. serves as investment manager. The filing was signed by James Silverman, President of Opaleye Management Inc. Prior to the October 22 transaction, the reported beneficial ownership stood at 2,948,610 shares, implied by the post-transaction figure of 2,970,000 shares following the first purchase.

What Was Disclosed

Opaleye Management Inc. disclosed two open-market purchases of Grace Therapeutics common stock on October 22 and October 26, 2026, totaling 87,801 shares acquired indirectly through Opaleye, L.P., resulting in reported indirect beneficial ownership of 3,036,411 shares.